137 related articles for article (PubMed ID: 10362335)
1. First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer.
Kakolyris S; Samonis G; Koukourakis M; Vlachonicolis J; Kalbakis K; Agelaki S; Chalkiadakis G; Sanidas E; Tsiftsis D; Georgoulias V
Am J Clin Oncol; 1999 Jun; 22(3):273-7. PubMed ID: 10362335
[TBL] [Abstract][Full Text] [Related]
2. First-line combination chemotherapy with mitoxantrone, methotrexate, vincristine and carboplatin (MIMOC) in advanced breast cancer.
Bafaloukos D; Samonis G; Klinaki A; Daliani D; Karvounis N; Bacoyiannis C; Karabelis A; Milonakis N; Kosmidis P
Eur J Cancer; 1993; 29A(6):851-3. PubMed ID: 8484975
[TBL] [Abstract][Full Text] [Related]
3. First-line chemotherapy of advanced breast cancer with a combination of mitoxantrone, methotrexate, and vincristine (MIMO).
Samonis G; Bafaloukos D; Margioris AN; Katsarma G; Toloudis P; Bacoyannis C; Karvounis N; Georgoulias V; Kosmidis P
Oncology; 1997; 54(5):371-5. PubMed ID: 9260597
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181).
Chang AY; Putt M; Pandya KJ; Harris J; Gelman R; Tormey DC; Falkson G
Am J Clin Oncol; 1998 Feb; 21(1):99-104. PubMed ID: 9499270
[TBL] [Abstract][Full Text] [Related]
6. Intensive chemotherapy with cisplatin, mitoxantrone, methotrexate and vincristine in metastatic breast cancer.
Queirolo P; Repetto L; Gardin G; Miglietta L; Guido T; Pronzato P; Rosso R
J Chemother; 1991 Jun; 3(3):194-7. PubMed ID: 1919659
[TBL] [Abstract][Full Text] [Related]
7. MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
Smith IE; Powles TJ
Oncology; 1993 Apr; 50 Suppl 1():9-15. PubMed ID: 8483562
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Fisher B; Dignam J; Wolmark N; DeCillis A; Emir B; Wickerham DL; Bryant J; Dimitrov NV; Abramson N; Atkins JN; Shibata H; Deschenes L; Margolese RG
J Natl Cancer Inst; 1997 Nov; 89(22):1673-82. PubMed ID: 9390536
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it.
Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Sismondi P; Giai M; Genta F; Pacini P; Distante V; Bolognesi A; Aldrighetti D; Farris A
J Clin Oncol; 2000 Jul; 18(14):2718-27. PubMed ID: 10894871
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Boccardo F; Rubagotti A; Bruzzi P; Cappellini M; Isola G; Nenci I; Piffanelli A; Scanni A; Sismondi P; Santi L
J Clin Oncol; 1990 Aug; 8(8):1310-20. PubMed ID: 2199618
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
Gazet JC; Ford HT; Gray R; McConkey C; Sutcliffe R; Quilliam J; Makinde V; Lowndes S; Coombes RC
Ann Oncol; 2001 May; 12(5):685-91. PubMed ID: 11432629
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer.
Gill PG; Gebski V; Snyder R; Burns I; Levi J; Byrne M; Coates A
Ann Oncol; 1993 Nov; 4(9):741-4. PubMed ID: 8280654
[TBL] [Abstract][Full Text] [Related]
14. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with methotrexate, carboplatin, mitoxantrone (Novantrone) and vincristine (Oncovin) in transitional-cell urothelial cancer.
Pectasides D; Mylonakis A; Antoniou F; Kostopoulou M; Triantaphyllis D; Papadopoulou M; Varthalitis J; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(2):139-44. PubMed ID: 9499188
[TBL] [Abstract][Full Text] [Related]
16. Cyclic sequential endocrine therapy for advanced breast cancer using a combination of tamoxifen and megestrol acetate.
Crawford DJ; George WD; Smith DC; Stewart M; Paul J; Leake RE
Oncology; 1994 Oct; 51 Suppl 1():13-8. PubMed ID: 7970503
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer.
Allegra JC
Semin Oncol; 1983 Jun; 10(2 Suppl 2):23-8. PubMed ID: 6306835
[TBL] [Abstract][Full Text] [Related]
19. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone, mitomycin-C, methotrexate combination chemotherapy with radiotherapy and/or surgery in stage III (T4B, NO-2, M0) breast cancer.
Raina V; Sharma A; Deo SV; Shukla NK; Mohanty BK; Goel A; Rath GK
J Assoc Physicians India; 1998 Nov; 46(11):926-9. PubMed ID: 11229215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
